Evidence-anchored
EN·ES
glp·helper
Find a Provider →
glphelper.com/wegovy
GLP-1 receptor agonistFDA-approved June 2021Rx · Subcutaneous injection · Once weekly

Wegovy® providers &
prescriptions near you

Dr. Fahad Akhtar, M.D.
Medically reviewed by Dr. Fahad Akhtar, M.D.
Physician at g1v.me, an affiliated practice

Physicians from the federal NPI registry, by state and city. Ask each office whether it prescribes Wegovy.[9]

average Wegovy weight loss →trial-anchored estimate
total providers
24,549
as of today
01 / Find
scopeUS
Search 24,549 results →
Get matched with a provider →Tell us your state and insurance. We’ll match you with a licensed Wegovy provider.
§ 01Medication factsheet
cited · last review 2026.05.19

An injectable medication for chronic weight management in adults. Same molecule as Ozempic, higher dose.

Wegovy is the brand name for semaglutide at the higher 2.4 mg dose. It is the same molecule as Ozempic, marketed by the same manufacturer for a different FDA-approved indication. It is a once-weekly subcutaneous injection in the GLP-1 receptor agonist class.[2][3]

In the STEP-1 randomized trial, 68 weeks of weekly 2.4 mg semaglutide produced a mean body-weight reduction of 14.9%, roughly 2.5× the weight loss seen at the Ozempic 1 mg dose. Wegovy is FDA-approved for chronic weight management in adults with a BMI ≥ 30, or ≥ 27 with at least one weight-related comorbidity such as hypertension or dyslipidemia.[1]

Ozempic is the same molecule on a different label, and Wegovy vs Ozempic compares the two on approved uses, doses, and price.

Bar chart of Wegovy dose strengths on the FDA label: 0.25 mg, 0.5 mg, 1 mg, 1.7 mg, 2.4 mg, 7.2 mg
Wegovy comes in 6 strengths: 0.25 mg, 0.5 mg, 1 mg, 1.7 mg, 2.4 mg, 7.2 mg. The chart shows what the label lists. A prescriber sets the dose.[1]
At a glanceNDC 0169-4525
Active ingredient
semaglutide
Drug class
GLP-1 receptor agonist
Manufacturer
Novo Nordisk
FDA approved
June 2021
Approved use
Chronic weight management in adults with obesity or overweight with weight-related comorbidities
Off-label use
Off-label use is uncommon. Ozempic is the FDA-approved formulation for type 2 diabetes
Administration
Subcutaneous injection · Once weekly
Available doses
0.25 mg · 0.5 mg · 1 mg · 1.7 mg · 2.4 mg · 7.2 mg
Half-life
≈ 7 days
Pregnancy
Discontinue ≥ 2 months before planned pregnancy
§ 02Clinical evidence
STEP 1 to 4 + SELECT (N = 17,604)

What the trials actually showed.

We summarize results from the STEP program, the global Phase IIIa trials Novo Nordisk submitted to the FDA for the weight-management indication, and the SELECT cardiovascular outcomes trial. Numbers below are means at the 68-week endpoint, 2.4 mg weekly dose.

STEP-1 randomized 1,961 adults with obesity to weekly 2.4 mg semaglutide vs placebo over 68 weeks. Mean body-weight reduction was 14.9% on semaglutide vs 2.4% on placebo. 86.4% of patients on semaglutide achieved ≥ 5% weight loss vs 31.5% on placebo.[4]
STEP / SELECT endpoint table2.4 mg / 68 wk
Weight change
−14.9%
vs −2.4% placebo, 68 wk[4]
≥ 5% weight loss
86.4%
vs 31.5% placebo[4]
≥ 15% weight loss
50.5%
vs 4.9% placebo[4]
Major adverse cardiac events
−20%
HR 0.80 vs. placebo (SELECT)[2]
Effect size varies with baseline characteristics and adherence. Individual response may differ materially.
average Wegovy weight loss →mapped to your starting weight
§ 04Safety & adverse events
from FDA label, sect. 6.1

Most Wegovy side effects are stomach and gut effects.

In Wegovy's weight trials at 2.4 mg, the most common side effects were nausea (44%), diarrhea (30%), vomiting (24%), and constipation (24%). These rates are higher than at Ozempic doses.[1] Serious events were rare but include pancreatitis, gallbladder disease, and an FDA boxed warning regarding thyroid C-cell tumors based on rodent data.[1]

Boxed warning. Contraindicated in personal or family history of medullary thyroid carcinoma (MTC) or in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN-2).
Effect
Frequency
Severity
Note
Nausea
44%
mild
More common than at Ozempic doses
Diarrhea
30%
mild
Most frequent during dose escalation phase
Vomiting
24%
mild
Slower titration reduces incidence
Constipation
24%
mild
Hydration + fiber recommended
Abdominal pain
20%
moderate
Pancreatitis
<0.3%
serious
Discontinue if confirmed; class warning
Gallbladder disease
1.6%
serious
Cholelithiasis risk elevated with rapid weight loss
Thyroid C-cell tumors
rodent data
boxed warning
Contraindicated in MTC or MEN-2 history
§ 05Cost & coverage, published, not gated
USD · monthly

What Wegovy costs, by how you pay.

The price you pay depends on your insurance plan, your diagnosis, and how you buy. Manufacturer self-pay programs cost far less than pharmacy retail. Here are the ranges.

Data sources: GoodRx national retail survey[6], CMS Part D formulary files[5], Novo Nordisk self-pay and savings pages.

Self-pay and savings card prices checked . Retail averages from May 2026.

Wegovy monthly cost by how you pay
Pharmacy retail (no insurance)$1,610 to $1,788per monthBrand-name retail average, May 2026[6]
NovoCare self-pay, pen$349per month0.25 to 2.4 mg. Wegovy HD 7.2 mg is $399. New patients pay $199 for the first two fills of 0.25 or 0.5 mg through Dec 31, 2026
NovoCare self-pay, pill$149 to $299per month1.5 mg $149, 4 mg $199, 9 and 25 mg $299
Commercial insurance (covered)$25 to $400per month copayVaries by PBM; many plans require BMI ≥ 30 + step therapy
Commercial insurance (denied)Typically deniedMost plans exclude weight-loss medications from formulary
Medicare GLP-1 Bridge$50per monthJul 1, 2026 to Dec 31, 2027, Part D enrollees who meet weight and health criteria[5]
Manufacturer savings cardas low as $25per monthCommercial insurance only, up to $100 a month in savings
§ 06Wegovy by state
50 states · 1009 towns

Find an Wegovy provider near you.

Choose your state or town to see physicians from the federal NPI registry. Ask each office whether it prescribes Wegovy.

Loading map

Or tap a pin on the map. 50 states, 1009 towns.

Wegovy in Alabama

18 towns · AL
Show all 18 towns in Alabama
See all providers in Alabama →

Wegovy in California

253 towns · CA
Show all 253 towns in California
See all providers in California →

Wegovy in Florida

101 towns · FL
Show all 101 towns in Florida
See all providers in Florida →

Wegovy in Illinois

63 towns · IL
Show all 63 towns in Illinois
See all providers in Illinois →

Wegovy in Oklahoma

14 towns · OK
Show all 14 towns in Oklahoma
See all providers in Oklahoma →

Wegovy in Texas

109 towns · TX
Show all 109 towns in Texas
See all providers in Texas →

Wegovy in Washington

37 towns · WA
Show all 37 towns in Washington
See all providers in Washington →
Find a GLP-1 provider
Weight loss doctors
Physicians listed in the federal NPI registry.
Weight loss clinics
Clinics running GLP-1 programs, telehealth & in-person.
Related GLP-1 research
plateaus on Wegovy and Ozempic
The plateau playbook: dose, habits, and what the trials say.
Wegovy dosage
The label's dose chart from 0.25 mg to 7.2 mg, plus the pill schedule.
§ 07Frequently asked: Wegovy

The questions people ask before they book.

Answers reviewed by the glp·helper Medical Team. Citations link to primary sources, never marketing copy.

FDA approval is for adults with a BMI ≥ 30, or ≥ 27 with at least one weight-related comorbidity (hypertension, type 2 diabetes, dyslipidemia). Adolescents 12+ with a BMI in the 95th percentile or higher were added to the label in December 2022.[1]